Skip to main content

Market Overview

MYND Life Sciences CEO Invited to Present at Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference


VANCOUVER, BC, Feb. 1, 2021 /CNW/ - MYND Life Sciences Inc. ("MYND") a life sciences company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce its CEO is presenting at Canaccord Genuity Group Inc.'s ("Canaccord Genuity") upcoming conference; New Paradigms and Treatment Approaches in Mental Health.

MYND CEO, Dr. Lyle Oberg will be presenting on February 3, 2021 at 10:30 A.M EST.

"We are incredibly excited to present at Canaccord's upcoming conference focussed on psychedelic and novel treatment approaches in mental health", stated Dr. Lyle Oberg, MYND's Chief Executive Officer. "Our team led by Dr. Wilf Jefferies continues to advance our psilocybin focussed R&D initiatives and we look forward to providing our current investor base and new potential shareholders with significant updates, including our anticipated listing date" continued Dr. Oberg.

For additional information on the conference, including any links that may be available or to access MYND's corporate presentation, please visit


MYND Life Sciences Inc. is a leading research and drug development company focussed on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on therapeutic approaches to treat diseases of the Central Nervous System using neuroactive agents including psychedelics and other compounds. Research and development is currently underway.

Investor Relations
Phone: 954-401-8686

Forward-Looking Information

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.   

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information.

Cision View original content to download multimedia:

SOURCE Mynd Life Sciences Inc.

Cision View original content to download multimedia:

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at